Therapeutic approaches to cystic fibrosis: Memorandum from a joint WHO/ICF(M)A meeting

March 1994
Bulletin of the World Health Organization;1994, Vol. 72 Issue 3, p341
Academic Journal
Cystic fibrosis is one of the commonest genetic diseases among Caucasians and represents an important cause of suffering and death among children and adults. In the past two decades marked prolongation of the life of patients with cystic fibrosis has been achieved as the result of improved case-finding and an extensive regimen of therapies. More recently, a variety of new approaches to therapy have been developed or proposed as the result of advances in cell physiology and molecular biology. This article summarizes the presentations and discussions made at a joint WHO/ICF(M)A (International Cystic Fibrosis (Mucoviscidosis) Association) meeting, held in Washington. DC, on 14 October 1992, and reviews the current status of possible therapies for cystic fibrosis and their implications for treatment in various countries of the world.


Related Articles

  • The Mutation Spectrum of the CFTR Gene in Cystic Fibrosis Patients from Bashkortostan. Korytina, G.F.; Viktorova, T.V.; Ivashchenko, T.E.; Baranov, V.S.; Khusnutdinova, E.K. // Molecular Biology;Jan/Feb2003, Vol. 37 Issue 1, p56 

    Mutations of CFTR were studied in patients with cystic fibrosis (CF) from Bashkortostan. In total, 15 mutations were observed and 51% of all mutant alleles identified. The most diagnostically significant mutations were delF508 (33.8%), 394delTT (3.52%), CFTRdele2,3(21kb) (1.41%), R334W (1.41%),...

  • Building an understanding of cystic fibrosis on the foundation of ABC transporter structures. Juan Mendoza; Philip Thomas // Journal of Bioenergetics & Biomembranes;Dec2007, Vol. 39 Issue 5/6, p499 

    Abstract  Cystic fibrosis (CF) is a fatal disease affecting the lungs and digestive system by impairment of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). While over 1000 mutations in CFTR have been associated with CF, the majority of cases are linked to the...

  • Novel Pharmaceutical Approaches for Treating Patients with Cystic Fibrosis. Saeed, Z.; Wojewodka, G.; Marion, D.; Guilbault, C.; Radzioch, D. // Current Pharmaceutical Design;Nov2007, Vol. 13 Issue 31, p3252 

    Before the cloning of the CFTR gene in 1989, there were relatively few treatment options for the many phenotypes associated with cystic fibrosis (CF). The advancement of research in areas such as immunology, molecular biology and pharmacology have provided new insights into the mechanism and...

  • Crystal structures of Burkholderia cenocepacia dihydropteroate synthase in the apo-form and complexed with the product 7,8-dihydropteroate. Morgan, Rachel E.; Batot, Gaëlle O.; Dement, Jennifer M.; Rao, Vincenzo A.; Eadsforth, Thomas C.; Hunter, William N. // BMC Structural Biology;2011, Vol. 11 Issue 1, p21 

    Background: The enzyme dihydropteroate synthase (DHPS) participates in the de novo synthesis of folate cofactors by catalyzing the formation of 7,8-dihydropteroate from condensation of p-aminobenzoic acid with 6-hydroxymethyl-7,8-dihydropteroate pyrophosphate. DHPS is absent from humans, who...

  • Modeling the Conformational Changes Underlying Channel Opening in CFTR. Rahman, Kazi S.; Cui, Guiying; Harvey, Stephen C.; McCarty, Nael A. // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator protein (CFTR) cause cystic fibrosis (CF), the most common life-shortening genetic disease among Caucasians. Although general features of the structure of CFTR have been predicted from homology models, the...

  • A disease called 'sixty-five roses'.  // Nature Structural Biology;Dec2002, Vol. 9 Issue 12, p887 

    Provides information on cystic fibrosis (CF). Cause of CF; Increase in efforts to educate the public about preventing CF; Initial screen for CF.

  • CYSTIC FIBROSIS NO LONGER A FATAL DISEASE. Braverman, Jane // Exceptional Parent;Nov2001, Vol. 31 Issue 11, p87 

    Provides information on cystic fibrosis. Background on the disease; Life expectancies of patients; Diagnosis of the illness; Treatment of the disease.

  • Activation of the epithelial Na+ channel (ENaC) requires CFTR CI- channel function. Reddy; Light, M.M. // Nature;11/18/1999, Vol. 402 Issue 6759, p301 

    Examines the ion channel regulation in the genetic disease cystic fibrosis. Dependence of epithelial Na+ channel on CFTR activity; Primary defect in Cl- channel permeability in cystic fibrosis; Factors in the reduced salt absorption in cystic fibrosis.

  • Editorial to conference proceedings. Bear, C.; Shori, D. K. // Pflugers Archiv European Journal of Physiology;Nov2001 Supplement 1, Vol. 443, pS1 

    The article presents information on the First International Conference on the Secretion Defect in Cystic Fibrosis that was held in May 1999 in Chalkidiki, Greece and was attended by about fifty scientists, research fellows and students. This conference was the first of a planned new series of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics